How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,281 results for

HIPAA

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients (PubMed)

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients To assess whether contralateral parenchymal enhancement reproduces as an independent biomarker for patient survival in an independent patient cohort from a different cancer institution.This is a HIPAA-compliant IRB approved retrospective study. Patients with ER-positive/HER2-negative operable invasive ductal carcinoma and preoperative

Full Text available with Trip Pro

2018 European radiology

182. Denosumab + Pembrolizumab in Patients With Stage IV Melanoma

staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Signed written informed consent and HIPAA authorization for release of personal health information. Age ≥ 18 years at the time of consent. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed

2018 Clinical Trials

183. Autoantibodies in Breast Cancer Detection

or women who have recently had a normal screening mammogram. The study team will enroll approximately 1,550 participants at Sanford Health in Sioux Falls, SD and Fargo, ND. Cohort A= 300 participants, Cohort B= 250 participants, Cohort C= 500 participants and Cohort D= 500 participants. Criteria Inclusion Criteria: Inclusion Criteria: All Cohorts: Women age 18 and older Understand and provide informed consent and HIPAA Authorization prior to initiation of any study-specific procedures Cohort A: Recent

2018 Clinical Trials

184. M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)

and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent and any locally-required authorization (e.g., HIPAA) obtained from the subject

2018 Clinical Trials

185. Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL

) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria - Unless otherwise noted, subjects must meet all of the following criteria to participate in this study: Written informed consent and HIPAA authorization for release of personal health information. Subjects must sign a consent to undergo cell procurement. Written informed consent to enroll in the CAR T-cell therapy trial must be obtained prior to lymphodepletion. Adults ≥18 years of age. Diagnosis of recurrent

2018 Clinical Trials

186. Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation

in the spreadsheet supplied with the IRB submission. The data will be disclosed only for analytical purposes.Confidentiality will be maintained by adhering to HIPAA guidelines. Only the PI and other study team members will have access to that data. Criteria Inclusion Criteria: Any patient who received or was potentially evaluated for radiotherapy since 2000 for benign or malignant etiologies in the definitive or palliative setting. Patients with comparatively similar diagnosis and disease status at UTSW

2018 Clinical Trials

187. TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

Sexes Eligible for Study: All Sampling Method: Probability Sample Study Population Any age population with a diagnosis of a TFE Renal Cell Carcinoma Criteria Inclusion Criteria: All patients of any age with a diagnosis of a TFE Renal Cell Carcinoma. Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent. Exclusion Criteria: Any patient that has not been diagnosed with TFE Renal Cell

2018 Clinical Trials

188. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

-up visit. Be willing to provide authorization for access to personal health information in conjunction with US Health Insurance Portability and Accountability Act (HIPAA). Exclusion Criteria: Have a clinically significant unstable medical condition or chronic disease, or malignancy. Had a medically significant illness within 30 days of screening. Have a known or suspected differential diagnosis of any of the other known forms of classic CAH. Have a history that includes bilateral adrenalectomy

2018 Clinical Trials

189. A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Inclusion Criteria: Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Age ≥ 18 years at the time of consent. ECOG Performance Status of ≤ 2 and/or sufficient to undergo both perioperative systemic chemotherapy and hepatic surgery as determined by surgical and medical oncology evaluations. Histologically confirmed hepatic-limited metastatic colorectal

2018 Clinical Trials

190. Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may

2018 Clinical Trials

191. Clinical Study on the Application of a Non-Invasive Micro-Focused Ultrasound With Visualization System for Skin Laxity (ULT-215)

. Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure. Exclusion Criteria: Open wounds or lesions in the area(s) to be treated. Severe or cystic acne on the area(s) to be treated. Presence of an active systemic or local skin disease that may affect wound healing. Active implants (e.g., pacemakers or defibrillators), or metallic implants in the treatment areas (dental implants not included.). Subcutaneous fillers Keloid scar

2018 Clinical Trials

192. Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction

subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14). Drug: Acellular Adipose Tissue (AAT) Participants (n=15) will be administered

2018 Clinical Trials

193. The Volumetric Analysis of Fat Grafting

. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Females or Males in good general health age 18 - 65 years of age Must be willing to give and sign a HIPAA form and informed consent form Must be willing

2018 Clinical Trials

194. Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life

participation, only the subject must sign a provision of informed consent and HIPAA compliant research authorization. Exclusion Criteria: Age less than10 years and greater than 21 years at study entry Greater than 2 diagnosed UTIs within last 12 months or symptomatic UTI at trial onset (UTI defined as the presence or ≥104 cfu/ml of a single bacterial strain in the presence of identified symptoms including but not limited to fever, flank or abdominal pain, change in urinary pattern or dysuria). Potential

2018 Clinical Trials

195. Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: provides written informed consent and HIPAA authorization before any study procedures are conducted; has a body mass index (BMI) < 37 kg/m2 is menopausal either naturally (at least 12 months amenorrheic) or 6 weeks after a bilateral salpingo-oophorectomy prior to natural menopause; subjects with hysterectomy only must have a serum FSH > 40 mIU/mL; has vulvovaginal atrophy with moderate to severe dyspareunia; has at least one

2018 Clinical Trials

196. Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC

therapy. Provision of written informed consent including HIPAA according to institutional guidelines prior to any study-specific procedures Patients must agree to research blood sampling to participate in study; Adequate organ and marrow function as defined by the following: Creatinine clearance ≥ 50 cc/min or serum Cr < 1.5 x institutional ULN Total bilirubin ≤ 1.5 x upper limit of normal (ULN) AST/ALT ≤ 2 x ULN without liver metastasis; ≤ 5 x ULN with liver metastasis Absolute neutrophil count (ANC

2018 Clinical Trials

197. Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

, HIPAA in the USA, EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations Age>=19 years at time of study entry Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy of >= 3months Histologically proven pancreatic ductal adenocarcinoma Resectable or borderline resectable based on AJCC Cancer staging system (8th ed) Chemotherapy -naïve for their pancreatic cancer Body weight

2018 Clinical Trials

198. Enhanced Pharmacist-Managed Anticoagulation Service in a University-based Family Medicine Clinic

monitoring Device: Home INR Monitoring The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface

2018 Clinical Trials

199. Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Willingness and ability to sign the informed consent form and Health Insurance Portability and Accountability Act (HIPAA) form. A study-specific informed consent form and a HIPAA form must be obtained in writing for all subjects prior to starting any study procedures

2018 Clinical Trials

200. Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

in all clinic visits. Patients living at home or in the community (assisted living acceptable). Able to swallow CT1812 capsules. Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening. Subjects must be capable of providing either written informed consent to the study procedures and for use of protected health information [Health Insurance Portability and Accountability Act (HIPAA) Authorization, if applicable]. Written informed consent also shall

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>